Regentys is developing ExtraCellular Matrix Hydrogel (ECMH), a tissue-engineered therapy designed to treat Ulcerative Colitis without the need for pharmacologic or surgical interventions. This first-in-class treatment addresses the significant issue of treatment-resistant patients, offering an alternative to colectomy for those who do not respond to existing biologic therapies.
Funding
$1.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Ulcerative Colitis (UC) patients who do not respond to existing biologic therapies face limited treatment options, often requiring colectomy. Current treatments may not induce deep remission, leaving patients with a reduced quality of life.
Solution
Regentys is developing ExtraCellular Matrix Hydrogel (ECMH), a first-in-class, non-pharmacologic, non-surgical regenerative medicine treatment for Ulcerative Colitis. ECMH is designed to promote tissue regeneration in the lower GI tract, offering an alternative for treatment-resistant patients. The therapy aims to induce deep remission and improve the quality of life for individuals suffering from UC.
Target Audience
The primary target audience includes patients suffering from Ulcerative Colitis, particularly those who have not responded to existing biologic therapies, as well as gastroenterologists and other medical professionals treating IBD.
Features
- Extracellular Matrix Hydrogel (ECMH) composition
- Non-pharmacologic approach, avoiding systemic drug exposure
- Non-surgical application, reducing invasiveness
- Designed for direct application to the affected area of the GI tract
- Aims to promote tissue regeneration and healing